Gemcitibine, an inhibitor of DNA synthesis and cell cycle, induces RKIP expression and synergizes with Sorafenib (a small molecule inhibitor targeting Vascular Endothelial Growth Factor Reeptor (VEGFR), Platelet-derived Growth Factor Receptor (PDGFR), and Raf) in non-small cell lung cancer (NSCLC) [45] and in pancreatic cancer [46] cell lines to block proliferation and increase apoptosis. The gene discussed is PEBP1; the disease is non-small cell lung carcinoma.